CoChat

Immune-checkpoint inhibitors induced diarrhea and colitis: a review of incidence, pathogenesis and management

Abu-Sbeih, Hamzah, Ali, Faisal S., Wang, Yinghong · 2020 · Current Opinion in Gastroenterology

The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.

Abstract

PURPOSE OF REVIEW: Diarrhea and colitis are among the most commonly encountered immune-mediated adverse events among patients receiving antiprogrammed cell death protein/ligand-1 (PD-1/L1) as well as anticytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibodies. With growing indications and widespread use of immune checkpoint inhibitors, it is imperative to summarize the current body of evidence concerning the incidence, pathogenesis, risk factors, diagnostic challenges, and treatment options currently available for the management of immune-mediated diarrhea and colitis. Additionally, with emerging evidence analyzing the resumption of immune checkpoint inhibitors, it is pivotal to summarize our current understanding and future challenges. RECENT FINDINGS: Immune-mediated diarrhea and colitis can potentially be a viable surrogate marker for improved survival as it is validated further in large-scale studies. Early endoscopic evaluation can aid in the identification of patients at risk of developing steroid refractory immune-mediated colitis, and hence can be chosen to receive early add-on therapy with infliximab, vedolizumab or fecal microbiota transplantation, an emerging treatment option for immune-mediated diarrhea and colitis. Resuming immune checkpoint inhibitors carries a manageable risk of recurrent diarrhea and colitis, with most cases being mild and effectively managed with immunosuppressive therapy. SUMMARY: As our understanding of immune-mediated diarrhea and colitis grows, it is likely that this clinicopathologic entity will represent more than just an adverse event. With a growing number of treatment options, the management algorithms for immune-mediated diarrhea/colitis are likely to evolve in the future.

Overview

Integrity signals

Registry

Crossref · 10.1097/mog.0000000000000593

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 38 references

Cited by

See all 30

Metadata

Authors
Abu-Sbeih, H., Ali, F. S., & Wang, Y.
Affiliations
  • Saint Joseph Hospital (US)
  • The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Ali, Faisal S.
Venue
Current Opinion in Gastroenterology
Published
2020-01
Volume
36
Issue
1
Pages
25-32
ISSN
0267-1379 (ISSN-L)
OpenAlex
W2980408506
Cited by
30
References
39
Citations by year
2026: 1 · 2025: 6 · 2024: 4 · 2023: 7 · 2022: 4 · 2021: 4 · 2020: 4
FWCI
0.29
Type
journal article
Language
en
Open access
closed
Locations
  • Current Opinion in Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
Keywords
immune checkpoint inhibitors, immune-related colitis, PD-1/PD-L1 inhibitors, CTLA-4 inhibitors, immune-related adverse events, steroid-refractory colitis, infliximab, vedolizumab, fecal microbiota transplantation, immunosuppressive therapy, endoscopy
MeSH terms
Immune Checkpoint Inhibitors, Colitis, Diarrhea, Humans, Neoplasms, Incidence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immune-checkpoint inhibitors induced diarrhea and colitis: a review of incidence, pathogenesis and management. https://app.cochat.ai/papers/10.1097/mog.0000000000000593
The paper
Abu-Sbeih, H., Ali, F. S., & Wang, Y. (2020). Immune-checkpoint inhibitors induced diarrhea and colitis: a review of incidence, pathogenesis and management. Current Opinion in Gastroenterology. https://doi.org/10.1097/mog.0000000000000593

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.